ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The clinical significance of Abl1 hasprompted extensive research into its inhibition as a therapeutic strategy,with tyrosine kinase inhibitors (TKIs) such as imatinib demonstratingefficacy in treating CML by selectively targeting the BCR–ABLfusion protein.6,7